Pharmacyclics llc - Company & Market Research Reports

Pharmacyclics LLC focuses on developing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a single-agent therapy used for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and waldenström's macroglobulinemia. It also has several product candidates in clinical development. The company was founded in 1991 and is headquartered in Sunnyvale, California.


Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market - Product Thumbnail Image

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

  • Report
  • 147 Pages
From
Hematological Tumor - Pipeline Review, H1 2014 - Product Thumbnail Image

Hematological Tumor - Pipeline Review, H1 2014

  • Report
  • 450 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight - Product Thumbnail Image

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

  • Drug Pipelines
  • 573 Pages
From
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - Product Thumbnail Image

Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020

  • Report
  • 109 Pages
From
Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends and Forecasts 2017 - 2022 - Product Thumbnail Image

Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends and Forecasts 2017 - 2022

  • Report
  • 211 Pages
From
Follicular Lymphoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Review, H2 2016

  • Report
  • 540 Pages
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016 - Product Thumbnail Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

  • Report
  • 1101 Pages
From
Mantle Cell Lymphoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Mantle Cell Lymphoma - Pipeline Review, H2 2016

  • Report
  • 426 Pages
From
Follicular Lymphoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Review, H1 2016

  • Report
  • 542 Pages
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016 - Product Thumbnail Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

  • Report
  • 1066 Pages
From
Hodgkin Lymphoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Hodgkin Lymphoma - Pipeline Review, H1 2016

  • Report
  • 361 Pages
From
Mantle Cell Lymphoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Mantle Cell Lymphoma - Pipeline Review, H1 2016

  • Report
  • 426 Pages
From
Follicular Lymphoma - Pipeline Review, H2 2015 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Review, H2 2015

  • Report
  • 478 Pages
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015 - Product Thumbnail Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

  • Report
  • 997 Pages
From
OpportunityAnalyzer: B-Cell Non-Hodgkin's Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024 - Product Thumbnail Image

OpportunityAnalyzer: B-Cell Non-Hodgkin's Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024

  • Drug Pipelines
  • 282 Pages
From
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Product Thumbnail Image

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015

  • Report
  • 781 Pages
From
Indolent Lymphoma - Pipeline Review, H1 2015 - Product Thumbnail Image

Indolent Lymphoma - Pipeline Review, H1 2015

  • Report
  • 173 Pages
From
Mantle Cell Lymphoma - Pipeline Review, H1 2015 - Product Thumbnail Image

Mantle Cell Lymphoma - Pipeline Review, H1 2015

  • Report
  • 336 Pages
From
Renal Cell Carcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Review, H2 2016

  • Report
  • 793 Pages
From
Loading Indicator
adroll